First Eagle Investment Management LLC cut its holdings in shares of Artivion, Inc. (NYSE:AORT – Free Report) by 45.5% in the third quarter, HoldingsChannel.com reports. The firm owned 377,608 shares of the company’s stock after selling 315,538 shares during the quarter. First Eagle Investment Management LLC’s holdings in Artivion were worth $8,617,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in AORT. Allworth Financial LP increased its stake in Artivion by 2,048.3% during the third quarter. Allworth Financial LP now owns 1,246 shares of the company’s stock worth $28,000 after purchasing an additional 1,188 shares during the period. Pinnacle Wealth Planning Services Inc. increased its holdings in Artivion by 362.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,379 shares of the company’s stock valued at $31,000 after buying an additional 1,081 shares during the last quarter. Versant Capital Management Inc raised its holdings in Artivion by 38.0% during the third quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock worth $48,000 after purchasing an additional 584 shares in the last quarter. Fulcrum Asset Management LLP purchased a new position in shares of Artivion during the third quarter worth about $49,000. Finally, Quantbot Technologies LP acquired a new position in shares of Artivion in the 2nd quarter valued at $103,000. 86.37% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, SVP Andrew Green sold 11,480 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the transaction, the senior vice president owned 40,160 shares in the company, valued at $1,002,795.20. This trade represents a 22.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 19,483 shares of company stock worth $503,031. Corporate insiders own 6.30% of the company’s stock.
Artivion Stock Performance
AORT stock opened at $18.55 on Friday. Artivion, Inc. has a 12 month low of $18.11 and a 12 month high of $48.25. The company has a quick ratio of 3.02, a current ratio of 4.42 and a debt-to-equity ratio of 0.82. The firm has a 50 day moving average of $22.35 and a two-hundred day moving average of $27.95. The company has a market capitalization of $905.30 million, a price-to-earnings ratio of 40.30 and a beta of 1.31.
Artivion (NYSE:AORT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. The company had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million. Artivion had a negative net margin of 3.65% and a positive return on equity of 5.12%.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Jefferies Financial Group started coverage on Artivion in a research note on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, November 4th. Canaccord Genuity Group reduced their price objective on shares of Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Finally, Citizens Jmp decreased their target price on Artivion from $48.00 to $42.00 and set a “market outperform” rating for the company in a research note on Friday, November 6th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.
Read Our Latest Analysis on Artivion
About Artivion
Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.
Recommended Stories
- Five stocks we like better than Artivion
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
